Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
06-08 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
06-08 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
16 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-icd-10-codes-recognize-fontan-associated-conditions-advancing-care-and-coverage-for-rare-congenital-heart-disease-community-302430453.html
https://www.prnewswire.com/news-releases/mezzion-pharmaceuticals-announces-dr-rahul-rathod-of-boston-childrens-hospital-and-harvard-medical-school-as-the-global-principal-investigator-for-the-confirmatory-pivotal-phase-3-trial-fuel-2-302077629.html
25 Apr 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mezzion-pharma-raises-nearly-40m-to-advance-a-first-to-market-treatment-option-for-fontan-patients-301807071.html
21 Feb 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mezzion-pharma-submits-protocol-for-confirmatory-pivotal-phase-3-trial-fuel-2-in-fontan-subjects-301751245.html
31 May 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/mezzion-pharma-receives-clear-fda-path-forward-for-the-approval-of-udenafil-for-single-ventricle-heart-disease-301558085.html
25 May 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/mezzions-new-drug-application-nda-for-its-orphan-drug-udenafil-for-the-treatment-of-single-ventricle-heart-disease-svhd-has-been-accepted-for-filing-by-the-fda-301299410.html
ABOUT THIS PAGE